| CDK4/6 inhibition triggers anti-tumour immunity S Goel, MJ DeCristo, AC Watt, H BrinJones, J Sceneay, BB Li, N Khan, ... Nature 548 (7668), 471-475, 2017 | 1214 | 2017 |
| Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised … S Loibl, J O'Shaughnessy, M Untch, WM Sikov, HS Rugo, MD McKee, ... The lancet oncology 19 (4), 497-509, 2018 | 706 | 2018 |
| Dissecting the heterogeneity of triple-negative breast cancer O Metzger-Filho, A Tutt, E De Azambuja, KS Saini, G Viale, S Loi, ... Journal of clinical oncology 30 (15), 1879-1887, 2012 | 511 | 2012 |
| Patterns of recurrence and outcome according to breast cancer subtypes in lymph node–negative disease: results from International Breast Cancer Study Group Trials VIII and IX O Metzger-Filho, Z Sun, G Viale, KN Price, D Crivellari, RD Snyder, ... Journal of clinical oncology 31 (25), 3083-3090, 2013 | 422 | 2013 |
| Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer KS Saini, S Loi, E de Azambuja, O Metzger-Filho, ML Saini, M Ignatiadis, ... Cancer treatment reviews 39 (8), 935-946, 2013 | 410 | 2013 |
| Genomic characterization of primary invasive lobular breast cancer C Desmedt, G Zoppoli, G Gundem, G Pruneri, D Larsimont, M Fornili, ... Journal of clinical oncology 34 (16), 1872-1881, 2016 | 310 | 2016 |
| Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01) E De Azambuja, MJ Procter, DJ Van Veldhuisen, D Agbor-Tarh, ... Journal of clinical oncology 32 (20), 2159-2165, 2014 | 264 | 2014 |
| Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries KS Saini, C Taylor, AJ Ramirez, C Palmieri, U Gunnarsson, HJ Schmoll, ... Annals of oncology 23 (4), 853-859, 2012 | 254 | 2012 |
| DNA methylation profiling reveals a predominant immune component in breast cancers S Dedeurwaerder, C Desmedt, E Calonne, SK Singhal, B Haibe‐Kains, ... EMBO molecular medicine, 2011 | 239 | 2011 |
| Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study EL Mayer, AC Dueck, M Martin, G Rubovszky, HJ Burstein, ... The lancet oncology 22 (2), 212-222, 2021 | 231 | 2021 |
| CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01) BC Pestalozzi, E Holmes, E de Azambuja, O Metzger-Filho, L Hogge, ... The lancet oncology 14 (3), 244-248, 2013 | 227 | 2013 |
| The natural history of hormone receptor-positive breast cancer MD Elgene Lim, O Metzger-Filho, EP Winer Oncology 26 (8), 688, 2012 | 193 | 2012 |
| Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial O Metzger Filho, A Giobbie-Hurder, E Mallon, B Gusterson, G Viale, ... Journal of Clinical Oncology 33 (25), 2772-2779, 2015 | 181 | 2015 |
| Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications R Barroso-Sousa, O Metzger-Filho Therapeutic advances in medical oncology 8 (4), 261-266, 2016 | 154 | 2016 |
| Adjuvant palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42/AFT-05/BIG-14-03) M Gnant, AC Dueck, S Frantal, M Martin, HJ Burstein, R Greil, P Fox, ... Journal of Clinical Oncology 40 (3), 282-293, 2022 | 133 | 2022 |
| Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data … CE Geyer, WM Sikov, J Huober, HS Rugo, N Wolmark, J O’Shaughnessy, ... Annals of Oncology 33 (4), 384-394, 2022 | 129 | 2022 |
| Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab OM Filho, G Viale, S Stein, L Trippa, DA Yardley, IA Mayer, VG Abramson, ... Cancer discovery 11 (10), 2474-2487, 2021 | 128 | 2021 |
| Bevacizumab and breast cancer: A meta‐analysis of first‐line phase III studies and a critical reappraisal of available evidence JR Rossari, O Metzger-Filho, M Paesmans, KS Saini, A Gennari, ... Journal of oncology 2012 (1), 417673, 2012 | 127 | 2012 |
| Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the BrighTNess randomized clinical trial M Golshan, S Loibl, SM Wong, JB Huober, J O’Shaughnessy, HS Rugo, ... JAMA surgery 155 (3), e195410-e195410, 2020 | 104 | 2020 |
| Pertuzumab: optimizing HER2 blockade O Metzger-Filho, EP Winer, I Krop Clinical Cancer Research 19 (20), 5552-5556, 2013 | 96 | 2013 |
